Uprichard David C Insider Trades

Insider Trading History

Track insider trading activity for Uprichard David C. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $33.1k 5,200 shares
Last Trade
Jun 25, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$87.9M 5,200 shares
$16,911.54
$6.36
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
Director
Holding Value $26.3k 5,200 shares
Last Trade
Jun 25, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$31.4k 5,200 shares
$6.03
$5.05
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
Holding Value $94.7k 18,750 shares
Last Trade
May 29, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$91.7k 18,750 shares
$4.89
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $119k 18,750 shares
Last Trade
May 29, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$864M 18,750 shares
$46,056.96
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $54.6k 8,576 shares
Last Trade
May 31, 2018 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$876M 8,576 shares
$102,188.88
$6.36
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
Holding Value $43.3k 8,576 shares
Last Trade
May 31, 2018 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$51.9k 8,576 shares
$6.05
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $12.7k 2,000 shares
Last Trade
May 30, 2017 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$630M 2,000 shares
$315,202.32
$6.36
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
Holding Value $10.1k 2,000 shares
Last Trade
May 30, 2017 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$12.5k 2,000 shares
$6.25
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $95.5k 15,000 shares
Last Trade
May 26, 2016 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.56B 15,000 shares
$370,359.69
$6.36
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
Holding Value $75.8k 15,000 shares
Last Trade
May 26, 2016 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$69k 15,000 shares
$4.60
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $95.5k 15,000 shares
Last Trade
May 22, 2015 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$10.4B 15,000 shares
$691,130.74
$6.36
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10
Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 CYCCP
Holding Value $75.8k 15,000 shares
Last Trade
May 22, 2015 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$92.1k 15,000 shares
$6.14
$5.05
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $57.3k 9,000 shares
Last Trade
May 22, 2014 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$24B 9,000 shares
$2,669,492.49
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $57.3k 9,000 shares
Last Trade
May 22, 2014 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$24B 9,000 shares
$2,669,492.49
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $45.5k 7,142 shares
Last Trade
May 22, 2013 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$18.4B 7,142 shares
$2,583,101.15
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $318k 50,000 shares
Last Trade
May 23, 2012 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$142B 50,000 shares
$2,841,670.44
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $318k 50,000 shares
Last Trade
May 24, 2011 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$463B 50,000 shares
$9,252,512.81
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $318k 50,000 shares
Last Trade
Mar 29, 2010 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$720B 50,000 shares
$14,392,797.00
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $318k 50,000 shares
Last Trade
Mar 27, 2009 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$121B 50,000 shares
$2,418,957.60
$6.36
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals CYCC
Director
Holding Value $159k 25,006 shares
Last Trade
Jun 05, 2008 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$56.8B 4,700 shares
$12,094,183.00
$6.36

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up